1. Human papillomavirus DNA testing as a screen for cervical cancer: a meta-analysis of randomized controlled trials.
- Author
-
Ding, Y. L., Liu, W. C., Chen, J. N., Wei, Y. F., Lu, C., Wang, L., Hou, X. L., Xie, Q., and Diao, H. Y.
- Abstract
Purpose: The aim was to evaluate the effectiveness of cervical screening when HPV DNA testing is implemented. Materials and Methods: Medline (PubMed) was searched and experts were contacted for references. Odds ratio (OR) and 95% confidence intervals (CI) were used as measures of effect sizes. Results: The rate of CIN3 and worse decreased about twofold, from 1.19% in round 1 to 0.67% in round 2, and CIN2 decreased from 1.70% in round 1 to 0.80% in round 2. When primary cervical screening with LBC was combined with HPV testing, there was a statistically significant reduction in the detection of CIN2 and CIN3+ at the next screening round compared with liquid-based cytology (LBC) alone. Conclusions: HPV DNA-based screening is more effective than cytology in CIN3 and invasive cervical cancers, by detecting persistent high-grade lesions earlier, and providing a longer low-risk period. However, in younger women, HPV screening leads to over-diagnosis of regressive CIN2. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF